[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:cic-rearranged-sarcoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":37,"states":38},"CIC-Rearranged Sarcoma",4,3,[8,16,23,30],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07194044","Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes",[12],"Phase 1","RECRUITING","2026-08-26T02:18:31.944757Z","2026-05-05T02:43:26.981537Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07089992","A Study of Pembrolizumab in People With Ultra-Rare Sarcomas",[27],"Phase 2","2026-08-26T02:16:48.735701Z","2026-07-05T05:32:16.733886Z",{"nct_id":31,"title":32,"phases":33,"status":34,"updated_at":35,"content_modified":36},"NCT06414434","BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:38:13.938630Z","2026-05-05T02:43:27.915820Z",[],[]]